Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274469 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 205
- Enrollment target
NCT00274469 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 205 participants.
The verdict
NCT00274469, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 205 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.
Interventions
- DRUG fulvestrant
- DRUG anastrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2006-02-06 |
| Est. Completion | 2017-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274469
The ClinicalTrials.gov registry entry for NCT00274469 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fulvestrant is the first listed.
NCT00274469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00274469 about?
NCT00274469 is a clinical study titled "A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer". The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.
What is the current status of trial NCT00274469?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 205 participants. The study started on 2006-02-06. Estimated completion is 2017-01-13.
What interventions are being tested in trial NCT00274469?
The interventions under investigation include: fulvestrant (DRUG), anastrozole (DRUG).
Who is sponsoring clinical trial NCT00274469?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.